Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of majo…
Biotechnology
US, New York [HQ]
Balance Sheet
11 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | 2.00 | 2.00 | 49.00 | 38.00 | 35.00 | 15.00 | 220.00 | 186.00 | -338.00 | 331.00 | 588.00 | |
|
Current
|
2.00 | 2.00 | 49.00 | 37.00 | 35.00 | 15.00 | 220.00 | 184.00 | 86.00 | 245.00 | 504.00 | |
| Cash And Equivalents | 2.00 | 2.00 | 48.00 | 36.00 | 34.00 | 13.00 | 219.00 | 183.00 | 86.00 | 200.00 | 386.00 | |
| Assets | 2.00 | 2.00 | 49.00 | 38.00 | 35.00 | 15.00 | 220.00 | 186.00 | -338.00 | 331.00 | 588.00 | |
| Accounts Receivables (AR) | - - | - - | - - | - - | - - | - - | - - | - - | - - | -37.00 | -57.00 | |
| Inventory | - - | - - | - - | - - | - - | - - | - - | - - | - - | 4.00 | 15.00 | |
| Short Term Investments | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Current Assets | - - | - - | - - | 1.00 | 1.00 | 1.00 | - - | - - | - - | 2.00 | 8.00 | |
|
Non Current
|
- - | - - | - - | - - | - - | - - | - - | 2.00 | 1.00 | 85.00 | 83.00 | |
| Property, Plant, Equipment (Net) | - - | - - | - - | - - | - - | - - | - - | 1.00 | - - | 1.00 | 7.00 | |
|
Intangible Assets
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | 59.00 | 53.00 | |
| Goodwill | - - | - - | - - | - - | - - | - - | - - | - - | - - | 10.00 | 12.00 | |
| Long Term Investments | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Non Current Assets | - - | - - | - - | - - | - - | - - | - - | - - | - - | 14.00 | 11.00 | |
| Liabilities | 4.00 | 5.00 | 2.00 | 16.00 | 18.00 | 14.00 | 41.00 | 72.00 | 70.00 | 221.00 | 397.00 | |
|
Current
|
4.00 | - - | 2.00 | 7.00 | 12.00 | 10.00 | 24.00 | 23.00 | 23.00 | 96.00 | 138.00 | |
| Accounts Payable | - - | - - | 1.00 | 2.00 | - - | - - | 7.00 | 2.00 | - - | 25.00 | 2.00 | |
| Short Term Debt | 3.00 | - - | - - | - - | 3.00 | 3.00 | 2.00 | 1.00 | - - | - - | 1.00 | |
| Deferred Revenue | - - | - - | - - | 2.00 | 2.00 | 3.00 | 10.00 | - - | - - | - - | - - | |
| Tax Payable | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Current Liabilities | - - | - - | - - | - - | 3.00 | - - | - - | 8.00 | 9.00 | 57.00 | 96.00 | |
|
Non Current
|
- - | 5.00 | - - | 9.00 | 6.00 | 3.00 | 17.00 | 48.00 | 49.00 | 125.00 | 258.00 | |
| Long Term Debt | - - | 4.00 | - - | 9.00 | 6.00 | 3.00 | 17.00 | 48.00 | 49.00 | 94.00 | 178.00 | |
| Leasing Obligations | - - | - - | - - | - - | - - | - - | - - | 1.00 | - - | - - | 7.00 | |
| Deferred Non Current Tax Liabilities | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Non Current Liabilities | - - | - - | - - | - - | - - | - - | -17.00 | - - | -49.00 | 31.00 | 80.00 | |
| Equity | -2.00 | -3.00 | -18.00 | -47.00 | -76.00 | -107.00 | -175.00 | -278.00 | -409.00 | 109.00 | 190.00 | |
| Stockholders' Equity | -2.00 | -3.00 | -18.00 | -47.00 | -76.00 | -107.00 | -175.00 | -278.00 | -409.00 | 109.00 | 190.00 | |
| Retained Earnings | -2.00 | -8.00 | -18.00 | -47.00 | -76.00 | -107.00 | -175.00 | -278.00 | -409.00 | -596.00 | -835.00 | |
| Common Stock | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Preferred Stock | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Profit | -2.00 | -6.00 | -10.00 | -27.00 | -28.00 | -30.00 | -69.00 | -105.00 | -134.00 | -197.00 | -239.00 | |
| Dividends | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Minority Interest | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Stockholders' Equity | - - | 5.00 | - - | - - | - - | - - | - - | - - | - - | 705.00 | 1,026.00 | |
| Loss Other Compr. Income | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - |